

Women's Cancer Prevention Office
(602) 322-1422



300 North 18th St.
Phoenix, Arizona 85006
FAX: (602) 253-4817

1006 0 JL
4001 North 3rd St., Ste. 230-A
Phoenix, Arizona 85012
FAX: (602) 264-0765

June 16, 2003
Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852

Dear Sir or Madam:

As a public health professional and advocate for women consumers, (we or I) would like to state our opposition and concern over the recent Notice (**Docket No. 02N-0434**) sent by your office to withdraw a rule (**Docket No. 91N-0245; Cosmetic Products Containing Certain Hormone Ingredients**) that currently allows women access to cosmetic topical progesterone products. We urge you to not withdraw this ruling. Taking away this rule would create unnecessary restrictions on women and limit their freedom to choose, purchase and enjoy these products as a way to look and feel better.

Moreover, your decision to potentially take away this consumer right seems arbitrary. The "reasons" stated in your letter are not based on fact or information, but rather a desire by the FDA to "reduce its backlog of paperwork" and to "focus its resources on public health issues." While we can appreciate FDA's desire to clear paperwork and focus on important "public health issues," those statements coupled with the intent of the Notice leads us to believe that your office may not understand the critical importance and value these products have for women.

Annually, more than a half a million women freely choose to use these products. Each year that number grows, as more women age and seek out these products as a personal choice for their well being. These women are not concerned about paperwork backlogs or if other health issues are more important to the FDA. For them, this is a personal issue and a personal choice. They do not want this choice taken away.

If FDA seeks to take away a ruling that has allowed access to these products, it should first provide all compelling evidence as to why these particular products should be limited. The Notice does not show any such evidence. The FDA Notice does not reference new scientific studies supporting a withdrawal of the rule nor did it state that it had additional information concerning the safety of these cosmetic products.


2002N-0434

C5

We believe that withdrawal of this ruling will ultimately have a devastating effect on women consumers across the county. Therefore, we respectfully urge you to reconsider the value of these products to women consumers and not withdraw this rule.

We truly appreciate your consideration of this matter.

Sincerely,



Linda Larkey, PhD

Director, Women's Cancer Prevention Office, Arizona Cancer Center

Research Assistant Professor, College of Public Health

University of Arizona

300 N. 18th Street

Phoenix, Arizona 85006